Perspective Therapeutics (NASDAQ: CATX) is a clinical-stage radiopharmaceutical company developing alpha-particle therapy candidates for cancer treatment. The company has no approved products and generates no commercial revenue as of its fiscal year ended December 31, 2025, operating entirely on capital raised through equity offerings. Its pipeline centers on Lead-212 (212Pb) targeted alpha therapy, using a proprietary isotope delivery system called VMT-α-GEN, a generator that produces 212Pb from Thorium-228 feedstock supplied under a 10-year contract with the National Isotope Development Center of the U.S. Department of Energy signed in January 2021. Perspective Therapeutics assembles radiopharmaceutical candidates by chelating 212Pb within a specialized chelator and attaching it to targeting peptides via proprietary linker technology. The company is incorporated in Delaware and led by CEO Johan (Thijs) Spoor. Lantheus Alpha Therapy, LLC holds a strategic investment position under an agreement dated January 2024. The company funds operations through at-will equity sales, including a 2024 ATM agreement covering up to $250.0 million in common stock.

Revenue model

No commercial revenue as of FY2025. Operations are funded through equity issuances, including an at-the-market offering program covering up to $250.0 million in common stock under a shelf registration statement effective May 24, 2024.

Products and services

VMT-α-GEN, a proprietary Lead-212 isotope generator system. Radiopharmaceutical drug candidates built by chelating 212Pb to cancer-targeting peptides using proprietary linker technology. All candidates are in clinical-stage development as of the 10-K filed March 16, 2026.

Customers and end markets

No commercial customers as of FY2025. End market is oncology, specifically patients enrolled in alpha-particle therapy clinical trials. Clinical supply is intended for trial sites using contract manufacturing organizations and company-owned manufacturing sites complying with FDA current good manufacturing practices.

Value-chain role

Vertically integrated clinical-stage developer controlling isotope supply (Thorium-228 feedstock from the DOE's National Isotope Development Center), generator manufacturing (VMT-α-GEN), and radiopharmaceutical assembly. Relies on third-party contract manufacturing organizations and component suppliers for clinical-scale production.

Geographic exposure

The filing references GDPR obligations indicating EU and UK clinical trial activity. U.S. incorporation (Delaware) and primary regulatory relationship with the FDA. No specific revenue geographic breakdown disclosed, consistent with pre-commercial status.

Source: SEC 10-K, filed 2026-03-16

Industry: Pharmaceutical Preparations Peers: Aligos Therapeutics Inc Ambrx Biopharma Cayman, Inc. Applied Molecular Transport Inc. Athenex, Inc. Beyondspring Inc Sellas Life Sciences Group Inc Oncternal Therapeutics, Inc. IN8bio Inc Rubius Therapeutics, Inc.